Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 9 |
| Clinical Trials and Average Enrollment by Country | 7 | 3 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 10 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 11 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 13 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 14 | 1 |
| Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials | 15 | 1 |
| Clinical Trials by Phase in G7 Countries | 16 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 17 | 1 |
| Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials | 18 | 1 |
| Clinical Trials by Phase in E7 Countries | 19 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 20 | 1 |
| Clinical Trials by Phase | 21 | 2 |
| In Progress Trials by Phase | 22 | 1 |
| Clinical Trials by Trial Status | 23 | 1 |
| Clinical Trials by End Point Status | 24 | 1 |
| Subjects Recruited Over a Period of Time | 25 | 1 |
| Clinical Trials by Sponsor Type | 26 | 1 |
| Prominent Sponsors | 27 | 3 |
| Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials | 28 | 2 |
| Prominent Drugs | 30 | 1 |
| Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) | 31 | 7 |
| Sep 14, 2016: GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma | 31 | 1 |
| Sep 09, 2016: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level | 31 | 1 |
| Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma | 31 | 3 |
| Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans | 34 | 1 |
| Aug 25, 2016: Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine | 34 | 1 |
| Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV s APO010 Study | 35 | 1 |
| Jul 25, 2016: Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma | 36 | 1 |
| Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients | 37 | 1 |
| Jul 07, 2016: Janssen and Johnson &Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio | 37 | 1 |
| Clinical Trial Profile Snapshots | 38 | 1624 |
| Appendix | 1662 | 4 |
| Abbreviations | 1662 | 1 |
| Definitions | 1662 | 1 |
| Research Methodology | 1663 | 1 |
| Secondary Research | 1663 | 1 |
| About GlobalData | 1664 | 1 |
| Contact Us | 1664 | 1 |
| Disclaimer | 1664 | 1 |
| Source | 1665 | 1 |